
Loading, please wait...

Loading, please wait...

A recent study highlights the potential of nanotechnology in oncology. Specifically, researchers investigated how dimercaptosuccinic acid (DMSA)-coated iron oxide nanoparticles (IONPs) affect breast cancer cell migration. Metastatic cells often undergo metabolic changes that make them sensitive to redox shifts. Therefore, targeted pro-oxidant therapies represent a promising strategy for modern cancer treatment.
The research demonstrates that DMSA-IONPs effectively trigger reactive oxygen species (ROS) production via the Fenton Reaction. This oxidative burst leads to actin carbonylation within the cancer cells. Consequently, these changes drive significant cytoskeletal rearrangements. The cells experience a reduction in area and a decrease in the number of invadosomes. Notably, these structural changes directly impair breast cancer cell migration and invasion capabilities.
Beyond structural impacts, the nanoparticles influence how tumor cells interact with their environment. They accumulate in endo-lysosomal compartments, which alters unconventional protein secretion pathways (UCPS). This process stimulates the release of multivesicular bodies while simultaneously blocking lysosomal and autophagosomal release. Such modifications shift the paracrine signals sent to endothelial cells. Ultimately, this disruption inhibits endothelial cell chemotaxis, which is vital for metastasis.
In conclusion, DMSA-IONPs offer a dual-action mechanism. They directly halt tumor cell movement and indirectly starve the tumor by interfering with its communication network. Furthermore, these findings suggest that nanoparticle-based therapies could become a cornerstone in managing metastatic breast cancer.
DMSA-IONPs induce oxidative stress, which leads to the carbonylation of actin. This process alters the cell's cytoskeleton, reducing its ability to move and invade surrounding tissues.
The Fenton Reaction occurs when iron oxide nanoparticles interact with intracellular hydrogen peroxide. This reaction generates highly reactive hydroxyl radicals, increasing oxidative stress to levels that damage cancer cell structures.
The nanoparticles modify protein secretion pathways in tumor cells. This change disrupts the paracrine communication between tumor and endothelial cells, further slowing the process of metastasis.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Daviu N et al. Oxidative stress induced by DMSA-IONPs impairs breast cancer cell migration and paracrine cell communication. J Nanobiotechnology. 2026 Apr 09. doi: 10.1186/s12951-026-04412-3. PMID: 41957669.
Portilla Y et al. DMSA-coated IONPs trigger oxidative stress, mitochondrial metabolic reprograming and changes in mitochondrial disposition, hindering cell cycle progression of cancer cells. Biomaterials. 2024 Jan;304:122409. doi: 10.1016/j.biomaterials.2023.122409.
Malik S et al. Targeting Oxidative Stress Biomarkers in Breast Cancer Development and the Potential Protective Effect of Phytochemicals. MDPI. 2025 May 23. doi: 10.3390/molecules30102456.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


New study reveals how DMSA-coated iron oxide nanoparticles impair breast cancer cell migration and paracrine communication through oxidative stress....
5 months ago

Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today

A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today

Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today

Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday

Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today